According to a review of previous studies, mutations in TET2 have been identified in 47%-100% of AITL cases, a prevalence significantly higher than the 14.6%-38% observed in PTCL-NOS [11]. The gene discussed is TET2; the disease is angioimmunoblastic T-cell lymphoma.